In the present review, we discuss the available data on the possible role of Nrf2 in obesity and metabolic syndrome and the feasibility of using Nrf2 as a therapeutic target in the clinical setting. This evidence concerns the gene NFE2L2 and obesity due to melanocortin 4 receptor deficiency.